Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women

키워드

참고문헌 (51)

1. Patseadou M, "Usage of the levonorgestrel-releasing intrauterine system(LNG-IUS)in adolescence : what is the evidence so far", Arch Gynecol Obstet, 295, pp.529~541 (2017)
2. Ortiz ME, "The mode of action of IUDs", Contraception, 36, pp.37~53 (1987)
3. Aoun J, "Effects of age, parity, and device type on complications and discontinuation of intrauterine devices", Obstet Gynecol, 123, pp.585~592 (2014)
4. World Health Organization, "Medical eligibility criteria for contraceptive use" (2015), World Health Organization
5. Tepper NK, "Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection", MMWR Morb Mortal Wkly Rep, 66, pp.990~994 (2017)
6. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice, "ACOG committee opinion. No. 337. Noncontraceptive uses of the levonorgestrel intrauterine system", Obstet Gynecol, 107, pp.1479~1482 (2006)
7. Bacon JL, "The menopausal transition", Obstet Gynecol Clin North Am, 44, pp.285~296 (2017)
8. Hale GE, "Atypical estradiol secretion and ovulation patterns caused by luteal outof-phase(LOOP)events underlying irregular ovulatory menstrual cycles in the menopausal transition", Menopause, 16, pp.50~59 (2009)
9. Davies J, "Heavy menstrual bleeding : an update on management", Thromb Res, 151(Suppl 1), pp.S70~S77 (2017)
10. Munro MG, "FIGO classification system(PALM-COEIN)for causes of abnormal uterine bleeding in nongravid women of reproductive age", Int J Gynaecol Obstet, 113, pp.3~13 (2011)
11. Curtis KM, "U.S. Medical Eligibility Criteria for Contraceptive Use, 2016", MMWR Recomm Rep, 65, pp.1~103 (2016)
12. Bitzer J, "Medical management of heavy menstrual bleeding : a comprehensive review of the literature", Obstet Gynecol Surv, 70, pp.115~130 (2015)
13. Grigorieva V, "Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas", Fertil Steril, 79, pp.1194~1198 (2003)
14. Kriplani A, "Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma", Int J Gynaecol Obstet, 116, pp.35~38 (2012)
15. Park DS, "Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis", Taiwan J Obstet Gynecol, 54, pp.412~415 (2015)
16. Yoo HJ, "The efficacy of the levonorgestrel-releasing intrauterine system in perimenopausal women with menorrhagia or dysmenorrhea", Arch Gynecol Obstet, 285, pp.161~166 (2012)
17. Desai RM, "Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women", J Midlife Health, 3, pp.20~23 (2012)
18. Küçük T, "Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia : a randomized, prospective, controlled clinical trial in female smokers", Clin Exp Obstet Gynecol, 35, pp.57~60 (2008)
19. Sanderson PA, "New concepts for an old problem : the diagnosis of endometrial hyperplasia", Hum Reprod Update, 23, pp.232~254 (2017)
20. Vishal Chandra, "Therapeutic options for management of endometrial hyperplasia", Journal of Gynecologic Oncology, 27(1), pp.1~25 (2016), 대한부인종양학회
21. Kurman RJ, "World Health Organization classification of tumours of female reproductive organs" (2014), International Agency for Research on Cancer (IARC) Press
22. Auclair MH, "Guideline No. 392-Classification and management of endometrial hyperplasia", J Obstet Gynaecol Can, 41, pp.1789~1800 (2019)
23. "Endometrial hyperplasia, management of (green-top guideline no. 67). RCOG/BSGE Joint Guideline" (2016)[URL]
24. Hatem Abu Hashim, "LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial", Journal of Gynecologic Oncology, 24(2), pp.128~134 (2013), 대한부인종양학회
25. Haimovich S, "Treatment of endometrial hyperplasia without atypia in peri-and postmenopausal women with a levonorgestrel intrauterine device", Menopause, 15, pp.1002~1004 (2008)
26. Doherty MT, "Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia : a systematic review and meta-analysis", PLoS One, 15, pp.e0232231~ (2020)
27. Machado RB, "The levonorgestrel-releasing intrauterine system : its effect on the number of hysterectomies performed in perimenopausal women with uterine fibroids", Gynecol Endocrinol, 29, pp.492~495 (2013)
28. Santoro N, "Reproductive hormones and the menopause transition", Obstet Gynecol Clin North Am, 38, pp.455~466 (2011)
29. Maia H Jr, "Aromatase expression in the eutopic endometrium of myomatous uteri : the influence of the menstrual cycle and oral contraceptive use", Gynecol Endocrinol, 23, pp.320~324 (2007)
30. Mercorio F, "The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia", Contraception, 67, pp.277~280 (2003)
31. Soysal S, "The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia : a prospective controlled trial", Gynecol Obstet Invest, 59, pp.29~35 (2005)
32. Santoro N, "Use of a levonorgestrel-containing intrauterine system with supplemental estrogen improves symptoms in perimenopausal women : a pilot study", Menopause, 22, pp.1301~1307 (2015)
33. Reed SD, "Premenopausal vasomotor symptoms in an ethnically diverse population", Menopause, 21, pp.153~158 (2014)
34. Depypere H, "The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy : a clinical review", Climacteric, 18, pp.470~482 (2015)
35. Boon J, "Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT", Maturitas, 46, pp.69~77 (2003)
36. Depypere HT, "A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause", Eur J Obstet Gynecol Reprod Biol, 153, pp.176~180 (2010)
37. Andersson K, "Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy", Obstet Gynecol, 79, pp.963~967 (1992)
38. Suhonen S, "Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy", Acta Obstet Gynecol Scand, 76, pp.145~150 (1997)
39. Suhonen SP, "Sustained-release subdermal estradiol implants : a new alternative in estrogen replacement therapy", Am J Obstet Gynecol, 169, pp.1248~1254 (1993)
40. Suhonen SP, "Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy", Am J Obstet Gynecol, 172(2Pt 1), pp.562~567 (1995)
41. Linton A, "Contraception for the perimenopausal woman", Climacteric, 19, pp.526~534 (2016)
42. Luukkainen T, "Five years' experience with levonorgestrelreleasing IUDs", Contraception, 33, pp.139~148 (1986)
43. Tepper NK, "Progestin-only contraception and thromboembolism : a systematic review", Contraception, 94, pp.678~700 (2016)
44. Brown WJ, "Identifying the energy gap : magnitude and determinants of 5-year weight gain in midage women", Obes Res, 13, pp.1431~1441 (2005)
45. Cagnacci A, "Menopause, estrogens, progestins, or their combination on body weight and anthropometric measures", Fertil Steril, 88, pp.1603~1608 (2007)
46. Wildman RP, "Adiposity and the menopausal transition", Obstet Gynecol Clin North Am, 38, pp.441~454 (2011)
47. Napolitano A, "Body composition and resting metabolic rate of perimenopausal women using continuous progestogen contraception", Eur J Contracept Reprod Health Care, 21, pp.168~175 (2016)
48. Conz L, "Levonorgestrel-releasing intrauterine system and breast cancer risk : a systematic review and meta-analysis", Acta Obstet Gynecol Scand, 99, pp.970~982 (2020)
49. Silva FR, "Is the levonorgestrel-releasing intrauterine system a risk factor for breast cancer", Acta Obstet Gynecol Scand, 100, pp.363~364 (2021)
50. Westhoff CL, "Hormonal contraception and breast cancer", Am J Obstet Gynecol, 219, pp.169.e1~169.e4 (2018)
51. Siegelmann-Danieli N, "Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective", Breast Cancer Res Treat, 167, pp.257~262 (2018)

관련 논문AI추천